Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook

Stock Track

Mar 05, 2025

BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.

The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:

37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million
31% year-over-year increase in total Q4 2024 revenue to $22.7 million
Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023
Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023
Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023

The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1186348054"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186348054\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186348054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 02:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186348054","market":"us","top_or_hot":-1,"title":"Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook","media":"Stock Track","content":"<p>BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.</p>\n\n<p>The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n<ul>\n<li>37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million</li>\n<li>31% year-over-year increase in total Q4 2024 revenue to $22.7 million</li>\n<li>Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023</li>\n<li>Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023</li>\n<li>Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023</li>\n</ul>\n</p>\n\n<p>The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-05 02:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.</p>\n\n<p>The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n<ul>\n<li>37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million</li>\n<li>31% year-over-year increase in total Q4 2024 revenue to $22.7 million</li>\n<li>Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023</li>\n<li>Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023</li>\n<li>Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023</li>\n</ul>\n</p>\n\n<p>The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLFS","symbol_name":"BioLife Solutions Inc.","start_time":0,"source_url":"","article_id":"1186348054","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186348054","pubTimestamp":1741111832,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioLife Solutions  stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:. 37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million. 31% year-over-year increase in total Q4 2024 revenue to $22.7 million. Improved GAAP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLFS":"BioLife Solutions Inc."},"translate_title":"股票赛道BioLife Solutions在强劲的第四季度盈利和积极的2025年前景后飙升5.10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLFS":1},"content_text":"BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.\nThe life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n\n37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million\n31% year-over-year increase in total Q4 2024 revenue to $22.7 million\nImproved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023\nPositive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023\nNarrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023\n\nThe company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}